ArticleCureus2021
The Prediction of Malignancy Risk in Thyroid Nodules Classified as Bethesda System Category III (AUS/FLUS) and the Role of Ultrasound Finding for Prediction of Malignancy Risk.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Integrated Ultrasound Features, Cytologic Subclassification, and Systemic Inflammatory Markers for Predicting Malignancy in Bethesda III Thyroid Nodules.Journal of clinical medicine · 2026Article
- Malignancy risk score in thyroid nodules with atypia of undetermined significance cytology: an approach based on cytological subgrouping and ultrasonographic data.Archives of endocrinology and metabolism · 2026Article
- A novel marker for predicting malignancy in patients with thyroid nodules diagnosed as AUS on initial cytology: thyroid hormone sensitivity.Frontiers in endocrinology · 2026Article
- The clinical value of repeat ultrasound-guided fine-needle aspiration biopsy in the management of Bethesda Category III thyroid nodules.Frontiers in endocrinology · 2026Article
- Diagnostic accuracy of thyroid nodules with indeterminate cytology when combined with ultrasonographic risk.Saudi medical journal · 2025Article
- Clinical Outcomes of Patients With Bethesda III or IV Cytology on Fine Needle Aspiration of Thyroid Nodules-A Retrospective Study.Endocrinology, diabetes & metabolism · 2025Article
- The Role of Ultrasound as a Predictor of Malignancy in Indeterminate Thyroid Nodules-A Multicenter Study.Medicina (Kaunas, Lithuania) · 2025Article
- Natural History of Cytologically Low-Risk Indeterminate Thyroid Nodules.The Journal of clinical endocrinology and metabolism · 2025Article
- Rates and Predictors of Malignancy in Bethesda III and IV Thyroid Nodules: A Prospective Study.Cureus · 2024Article
- Prevalence of malignancy in thyroid nodules with AUS cytopathology: A retrospective cross-sectional study.Journal of family medicine and primary care · 2024Article
- Ultrasonographic predictors of thyroid cancer in Bethesda III and IV thyroid nodules.Frontiers in endocrinology · 2024Article
- The Role of "Critical" Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules.Medicina (Kaunas, Lithuania) · 2023Article
- Current controversies in the management of patients with indeterminate thyroid nodules.Saudi medical journal · 2023Review
- The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules.Journal of Taibah University Medical Sciences · 2023Article
- Assessment of Preoperative TSH Serum Level and Thyroid Cancer Occurrence in Patients with AUS/FLUS Thyroid Nodule Diagnosis.Biomedicines · 2022Article
- Systematic review and meta-analysis: diagnostic value of different ultrasound for benign and malignant thyroid nodules.Gland surgery · 2022Article
- Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective To predict the risk of malignancy in category III of the Bethesda System for Reporting Thyroid Cytopathology "Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS)" at King Abdulaziz Medical City, Riyadh, Saudi Arabia. It also intends to determine other possible contributing predictors of malignancy in thyroid nodules such as age, sex, and ultrasound (US) findings. Method This retrospectively designed study included 187 patients (mean age, 43.9 ± 14.1 years) with thyroid nodules, which were diagnosed as AUS/FLUS and all patients included had total thyroidectomy or lobectomy between January 2013 and December 2018 at King Abdulaziz Medical City in Riyadh, Saudi Arabia. The electronic medical records, US images, and final cytopathology and histopathology reports were reviewed and analyzed. Result The overall incidence of AUS/FLUS was (46.5%). Multivariate analysis of US features revealed that malignancy was significantly associated with nodules with irregular margins, microcalcification, multiple numbers (P < 0.001), and hypoechogenicity (P 0.04). Conclusion Despite the high rate of malignancy of nodules AUS/FLUS, it is still consistent with previously reported studies. The highly suspicious ultrasound features (irregular margins, microcalcification, multiple nodules, and hypoechogenicity) could be helpful in the diagnosis of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.